Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 2/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10547382 | 0.85 | GABRP (0.45) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL15078308 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL2234661 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL1870024 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL29526116 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6364139 | 0.77 | PARP1 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15820380 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL10070177 | 0.76 | GABRA1 (0.50) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL23034317 | 0.75 | STING1 (0.47) | SMN1; SMN2HTTNPC1 | |
| SCHEMBL18686954 | 0.74 | GABRR1 (0.45) | KDM4EALDH1A1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2017277-A1 | Thiophene-imidazopyridines | 4SC AG (DE) | 2009-01-21 | — | — | EP | claimed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | claimed |
| EP-0551432-A1 | 4,5,6,7-TETRAHYDRO-1H-IMIDAZO 4,5-C]PYRIDINE DERIVATIVES AND ANALOGUES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-07-21 | — | — | EP | claimed |
| US-4812462-A | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1989-03-14 | — | — | US | claimed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| EP-4114836-A1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | Theravance Biopharma R&D IP, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| EP-3908319-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Phase Bio Pharmaceuticals, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3837258-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020146532-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SPARKS STEVEN (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-3555064-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1558611-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004039803-A2 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-0531876-A2 | Imidazoindolizine derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| EP-0245637-B1 | 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4816463-A | HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 1989-03-28 | — | — | US | disclosed |
| US-4812462-A | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1989-03-14 | — | — | US | disclosed |
| EP-0245637-A1 | 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | KDM4E 3779/4885ALDH1A1 908/4885RAB9A 1230/4885 |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | PIKFYVE, PIP4K2B, PIP5K1B | KDM4E 1387/4885ALDH1A1 3695/4885RAB9A 2522/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | KDM4E 3296/4885ALDH1A1 554/4885RAB9A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.